COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,300 Articles (22,772 medRxiv, 8,528 bioRxiv)

Most recent first Previous |  Page 920: Articles 9191-9200  | Next

Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2
Dicks, M. D. J., Rose, L. M., Bowman, L. A. H., Graham, C., Doores, K. J., Malim, M. H., Draper, S. J., Howarth, M., Biswas, S.
10.1101/2022.02.20.480711 — Posted: 2022-02-22
Understanding the immunological landscape of England during SARS-CoV2 Omicron variant wave
Shingleton, J., Dyke, S., Herrick, A., Finnie, T.
10.1101/2022.02.21.22271270 — Posted: 2022-02-22
Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection
Stegger, M., Edslev, S. M., Sieber, R. N., Ingham, A. C., Ng, K. L., Tang, M.-H. E., Alexandersen, S., Fonager, J., Legarth, R., Utko, M., Wilkowski, B., Gunalan, V., Bennedbaek, M., Byberg-Grauholm, J., Moeller, C. H., Christiansen, L. E., Svarrer, C. W., Ellegaard, K., Baig, S., Johannesen, T. B., Espenhain, L., Skov, R., Cohen, A. S., Larsen, N. B., Soerensen, K. M., White, E. D., Lillebaek, T., Ullum, H., Krause, T. G., Fomsgaard, A., Ethelberg, S., Rasmussen, M.
10.1101/2022.02.19.22271112 — Posted: 2022-02-22 Discussion: Onsite
Influenza vaccination reveals and partly reverses sex dimorphic immune imprints associated with prior mild COVID-19
Sparks, R., Lau, W. W., Liu, C., Han, K. L., Vrindten, K. L., Sun, G., Cox, M., Andrews, S. F., Bansal, N., Failla, L. E., Manischewitz, J., Grubbs, G., King, L. R., Koroleva, G., Leimenstoll, S., Snow, L., OP11 Clinical Staff, , Chen, J., Tang, J., Mukherjee, A., Sellers, B. A., Apps, R., McDermott, A. B., Martins, A. J., Bloch, E. M., Golding, H., Khurana, S., Tsang, J. S.
10.1101/2022.02.17.22271138 — Posted: 2022-02-22
Examining disparities relating to service reach and patient engagement with COVID-19 remote home monitoring services in England: a mixed methods rapid evaluation
Crellin, N. E., Herlitz, L., Sidhu, M. S., Ellins, J., Georghiou, T., Litchfield, I., Massou, E., Ng, P. L., Sherlaw-Johnson, C., Tomini, S. M., Vindrola-Padros, C., Walton, H., Fulop, N. J.
10.1101/2022.02.21.22270793 — Posted: 2022-02-22
Quantifying the effect of isolation and negative certification on COVID-19 transmission
Takeshita, J.-i., Murakami, M., Kamo, M., Naito, W., Yasutaka, T., Imoto, S.
10.1101/2022.02.20.22270449 — Posted: 2022-02-22
Persisting pulmonary dysfunction in pediatric post-acute Covid-19
Heiss, R., Wagner, A. L., Tan, L., Schmidt, S., Regensburger, A. P., Ewert, F., Mammadova, D., Buehler, A., Vogel-Claussen, J., Voskrebenzev, A., Rompel, O., Nagel, A. M., Levy, S., Bickelhaupt, S., May, M. S., Uder, M., Metzler, M., Trollmann, R., Woelfle, J., Knieling, F.
10.1101/2022.02.21.22270909 — Posted: 2022-02-22
COVID-19 vaccine incentive scheduling using an optimally controlled reinforcement learning model
Stuckey, K., Newton, P.
10.1101/2022.02.17.22271145 — Posted: 2022-02-22
SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway
Sarjomaa, M., Diep, L. M., Zhang, C., Tveten, Y., Reiso, H., Thilesen, C., Nordbo, S. A., Berg, K. K., Aaberge, I., Pearce, N., Kersten, H., Vandenbroucke, J. P., Eikeland, R., Fell, A. K. M.
10.1101/2022.02.16.22271075 — Posted: 2022-02-21
At least three doses of leading vaccines essential for neutralization of SARS-CoV-2 Omicron variant
Singanallur, N. B., Jansen van Vuren, P., McAuley, A. J., Bruce, M. P., Kuiper, M. J., Gwini, S., Riddell, S., Goldie, S., Drew, T. W., Blasdell, K. R., Tachedjian, M., Mangalaganesh, S., Chahal, S., Caly, L., Druce, J. D., Juno, J. A., Kent, S., Wheatley, A. K., Vasan, S. S.
10.1101/2022.02.20.22271237 — Posted: 2022-02-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).